Menu
Recruiting NCT06102486

MCI Speech in Noise

Observational Mild Cognitive Impairment

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Mild Cognitive Impairment. Basic parameters: 55 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Speech Perception in Noise as an Improved Marker for Neurocognitive Dysfunction

Overview

The purpose of this study is to determine whether people with MCI (Mild Cognitive Impairment) and healthy comparison subjects differ with respect to their ability to hear soft sounds and how their brain understands and processes sound. The investigators are also evaluating, within those with MCI, whether the hearing tests are associated with neurocognitive functioning. The investigators are interested in learning whether changes in cognition in those with MCI can be detected using tests of how the brain processes sound. The investigators hypothesize that participants with MCI will score worse on both hearing tests and neurocognitive tests than participants without MCI. Participants are asked to complete multiple types of hearing tests, take a series of neurocognitive tests, and complete a few questionnaires.

Primary outcome measures

  • Hearing-in-Noise Test Performance [Time frame: 1 time point (takes 15 minutes)]
  • Triple Digit in Noise Test Performance [Time frame: 1 time point (takes 15 minutes)]
  • Size of auditory neural response in background noise [Time frame: 1 time point (takes 45 minutes)]
  • Timing of auditory neural response in background noise [Time frame: 1 time point (takes 45 minutes)]

Eligibility criteria

Inclusion criteria

  • Adults diagnosed with or suspected to have MCI (for MCI group) or are cognitively normal (for Control group)
  • Absence of other risk factors that might affect CAP (Central Auditory Processing) performance (e.g., active ear infections, congenital developmental delay, severe hearing loss)
  • Age 55-80
  • Normal hearing sensitivity (<40 dB HL Pure Tone Average (average of 500, 1000, 2000 Hz) thresholds bilaterally
  • Normal middle ear function defined by tympanometry (0.3-2.0 ml)
  • Native English speaker

Exclusion criteria

  • Active ear infections or abnormal middle ear pathology
  • Other health condition prohibiting the completion of the CAP test battery
  • Mild to profound peripheral hearing loss (>40 dB (decibel) HL (hearing loss) Pure Tone Average (average of 500, 1000, 2000 Hz) bilaterally
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Prisoners
  • History of CNS (Central Nervous System) disorder that might severely impact cognitive function (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, neurosyphilis, intracranial tumors, history of significant head trauma with loss of consciousness (≥30 min), and cerebrovascular disease)
  • Severe mental illness (e.g., schizophrenia, bipolar disorder)
  • Current, uncontrolled medical condition that could affect cognition (e.g., hypertension)
  • History of substance use disorder within the (other than nicotine/caffeine)
  • Non-correctable severe hearing or vision loss
  • Use of "Cognition Enhancing Drugs"
  • Frequent, severe headaches (occasional headaches or migraines are fine)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

United States · 1 center
  • Space Medicine Lab at Dartmouth-Hitchcock Medical Center — Lebanon

Identifiers

NCT: NCT06102486 · STUDY02002079

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗